1 |
NCT03272633 |
Not yet recruiting |
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies |
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia in Remission
- Hematopoietic Cell Transplantation Recipient
- (and 16 more...)
|
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Biological: Irradiated Allogeneic Cells
|
Interventional |
Phase 2 |
- Rutgers, The State University of New Jersey
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease response in patients who receive irradiated haploidentical cells (IHC)
- Incidence of toxicities associated with administration of irradiated haploidentical cells (IHC) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Induction of host T cells reactive with tumor associated epitopes
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT03272633 |
011702 NCI-2017-01537 Pro20170000537 P30CA072720 |
|
March 5, 2018 |
April 30, 2020 |
April 30, 2020 |
September 5, 2017 |
January 24, 2018 |
|
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
|
2 |
NCT02978625 |
Recruiting |
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers |
- Adenoid Cystic Carcinoma
- Adnexal Carcinoma
- Apocrine Carcinoma
- (and 29 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
- Biological: Talimogene Laherparepvec
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Best overall response rate to talimogene laherparepvec alone as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Best overall response rate to talimogene laherparepvec and nivolumab combination therapy as assessed by RECIST version 1.1
- Durable response rate defined as complete response or partial response lasting >= 6 months
- (and 7 more...)
|
68 |
All |
18 Years and older (Adult, Senior) |
NCT02978625 |
NCI-2016-01804 CINJ #091701 10057 UM1CA186716 |
|
September 18, 2017 |
January 31, 2019 |
January 31, 2019 |
December 1, 2016 |
April 3, 2018 |
|
- Los Angeles County-USC Medical Center
Los Angeles, California, United States - USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States - Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States - University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, United States
|
3 |
NCT02562443 |
Recruiting |
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA |
- Myelodysplastic Syndrome
- MDS
- Refractory Anemia With Excess Blasts
- RAEB
|
- Drug: rigosertib
- Drug: Any approved or standard-of-care therapy
- Drug: best supportive care (BSC)
|
Interventional |
Phase 3 |
- Onconova Therapeutics, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival of all randomized patients and overall survival of patients scored as IPSS-R very high risk.
- Overall survival of patients with monosomy 7 chromosomal aberrations.
- Overall survival of patients with trisomy 8 chromosomal aberrations.
- (and 4 more...)
|
360 |
All |
18 Years to 81 Years (Adult, Senior) |
NCT02562443 |
Onconova 04-30 2015-001476-22 |
INSPIRE |
October 2015 |
June 2019 |
December 2019 |
September 29, 2015 |
April 23, 2018 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States - USC Norris Comprehensive Cancer Center
Los Angeles, California, United States - UCLA Medical Center
Los Angeles, California, United States - (and 180 more...)
|
4 |
NCT01582763 |
Recruiting |
International Guillain-Barré Syndrome Outcome Study |
- Guillain-Barré Syndrome
- Miller Fisher Syndrome
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Guillain-Barre Syndrome(GBS) disability score and Medical Research Council(MRC) sumscore
- Overall Neuropathy Limitations Scale (ONLS)
- Fatigue Severity Scale (FSS)
- (and 2 more...)
|
4000 |
All |
Child, Adult, Senior |
NCT01582763 |
MEC-2011-477 3290 |
IGOS |
May 2012 |
June 2017 |
January 2019 |
April 23, 2012 |
January 5, 2017 |
|
- Barrows Neurological Institute
Phoenix, Arizona, United States - UC Irvine Health
Orange, California, United States - Yale University School of medicine
New Haven, Connecticut, United States - (and 125 more...)
|
5 |
NCT02223052 |
Recruiting |
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies |
- Hematological Neoplasms
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- (and 17 more...)
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetics Cmax - Stage I (Bioequivalence)
- Pharmacokinetics Tmax - Stage I (Bioequivalence)
- Pharmacokinetics AUC-t - Stage I (Bioequivalence)
- (and 14 more...)
|
90 |
All |
18 Years and older (Adult, Senior) |
NCT02223052 |
CC-486-CAGEN-001 |
|
October 27, 2014 |
March 19, 2019 |
March 19, 2019 |
August 22, 2014 |
March 2, 2018 |
|
- Scottsdale Healthcare Research Institute
Scottsdale, Arizona, United States - Mayo Clinic - Arizona
Scottsdale, Arizona, United States - University of Arizona Cancer Center
Tucson, Arizona, United States - (and 8 more...)
|
6 |
NCT03233204 |
Recruiting |
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 29 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (complete response/partial response) determined using Response Evaluation Criteria in Solid Tumors version 1.1
- Progression free survival (PFS)
- Incidence of toxicity evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Pharmacokinetics (PK) of olaparib
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03233204 |
NCI-2017-00766 APEC1621H U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 28, 2017 |
April 24, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 63 more...)
|
7 |
NCT03155620 |
Recruiting |
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 32 more...)
|
- Procedure: Biopsy
- Procedure: Biospecimen Collection
- Drug: Ensartinib
- (and 10 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (complete response/partial response) assessed according to Response Evaluation Criteria in Solid Tumors version 1.1
- Incidence of toxicity assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Incidence of research biopsy related target toxicity
- (and 2 more...)
|
1500 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03155620 |
NCI-2017-01251 APEC1621SC U10CA180886 |
|
July 24, 2017 |
September 30, 2027 |
September 30, 2027 |
May 16, 2017 |
April 24, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 91 more...)
|
8 |
NCT02867592 |
Recruiting |
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors |
- Adrenal Cortex Carcinoma
- Adult Alveolar Soft Part Sarcoma
- Adult Clear Cell Sarcoma of Soft Parts
- (and 30 more...)
|
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response assessed by Response Evaluation Criteria in Solid Tumors version 1.1
- Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Pharmacokinetics (PK) parameters of cabozantinib s-malate
|
146 |
All |
2 Years to 30 Years (Child, Adult) |
NCT02867592 |
NCI-2016-01258 ADVL1622 U10CA180886 |
|
May 8, 2017 |
November 21, 2018 |
November 21, 2018 |
August 16, 2016 |
April 24, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 119 more...)
|